The University of Wisconsin Department of Human Oncology proudly announces the promotion of faculty member John Floberg, MD, PhD to Associate Professor (CHS), effective June 29, 2025. We are grateful for Dr. Floberg’s dedication to innovative research, excellent patient care and education; all which move the field of Radiation Oncology forward.
Faculty in the UW School of Medicine and Public Health are employed within distinct career tracks, including clinical health sciences (CHS) and clinician teacher (CT).
Dr. Floberg completed his MD and PhD at the University of Wisconsin-Madison, and his residency in radiation oncology at Washington University in St. Louis. Clinically, Dr. Floberg focuses on the treatment of genitourinary cancers. He collaborates with urologists, medical oncologists, radiologists, pathologists and other specialists to provide his patients with the best care possible and enjoys teaching residents and medical students in the clinic. He trains them in state-of-the-art techniques and treatments including high-dose-rate prostate brachytherapy, stereotactic body radiation therapy (SBRT), MRI-guided radiation therapy and targeted radiopharmaceuticals. Dr. Floberg’s research focuses on advanced imaging, such as positron emission tomography (PET) and MRI.
Dr. Floberg has been integrally involved with theranostics at the University of Wisconsin. He has helped establish a multidisciplinary theranostics program with the Division of Nuclear Medicine, including a clinical theranostics dosimetry program that enables a patient centered and personalized approach to radiopharmaceutical therapies. He also serves on the executive committee for the University of Wisconsin Carbone Cancer Center’s Initiative for Theranostics and Particle Therapy, helping lead this initiative’s education efforts.
Dr. Floberg is also heavily involved in clinical trials. He has been one of the Carbone Cancer Center’s top accruing physicians, he serves as the national PI for a phase 2 clinical trial run through the NCI’s Experimental Therapeutics Clinical Trials Network, and also works on a national level with the ECOG/ACRIN and NRG cooperative groups.